A Phase 1 interventional study of SGN-CD19A in Burkitt Lymphoma, Lymphoma, Follicular and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen Inc.. Completed at 6 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-10-19.
Sponsored by Seagen Inc. · Phase 1, Interventional, and Treatment
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
392 studies on the registry are indexed under Burkitt Lymphoma; 114 are open to participants now.
This study's enrollment of 64 is above the median of 41 across 354 interventional studies indexed under Burkitt Lymphoma.
Browse Burkitt Lymphoma studies →Seagen Inc. is the lead sponsor of 84 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
Drug: SGN-CD19A
SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
Incidence of adverse events
Time frame: Through 1 month post last dose
Incidence of laboratory abnormalities
Time frame: Through 1 month post last dose
Objective response according to revised response criteria for malignant lymphoma (Cheson 2007)
Time frame: Through up to approximately 6 week post last dose
Duration of response
Time frame: Until disease progression or start of new anticancer treatment, an expected average of 6 months
Overall survival
Time frame: Until death or study closure, an expected average of 1 year
Blood concentration of SGN-CD19A and metabolites
Time frame: Through up to approximately 6 weeks post last dose
Incidence of antitherapeutic antibodies
Time frame: Through up to approximately 6 weeks post last dose
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seagen Inc.